LGVN News and Press, Longeveron Inc. From 11/18/21

3 Penny Stocks to Add to Your November 2021 Watchlist While November is more than halfway done, penny stocks continue to see bullish momentum. Although it has been a shaky month and past few months for both penny stocks and blue chips , it’s clear that investors are hoping fo...

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest moves in the market today belongs to Longeveron (NASDAQ: LGVN ). Currently, LGVN stock is up approximately 180% on more than 100 times the average daily volume. Source: luchschenF / Shutterstock....

Microcap stock Longeveron (LGVN +180.3%) is soaring today after announcing that it has received FDA Rare Pediatric Disease Designation for Lomecel-B, its candidate for Hypoplastic Left Heart Syndrome. Average volume for the stock is 121,844. As of 1215p, ~161M shares have traded hands to...

Longeveron Inc. (NASDAQ: LGVN) has received approval for Rare Pediatric Disease Designation for Lomecel-B by the FDA to treat Hypoplastic Left Heart Syndrom.  HLHS is a rare life-threatening congenital heart defect in infants.  Lomecel-B is an investigational allogen...

Longeveron (NASDAQ:LGVN) gains 10.7% premarket after the FDA granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Rare Pediatric Disease status prov...

Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration (FD...

Longeveron Inc. (LGVN) Q3 2021 Earnings Conference Call November 12, 2021 08:30 AM ET Company Participants Brendan Payne - Stern IR Geoff Green - Chief Executive Officer Joshua Hare - Co-Founder, Chief Science Officer and Chairman James Clavijo - Chief Financial Officer Presentation Operator ...

Longeveron (NASDAQ:LGVN): Q3 GAAP EPS of -$0.25. Revenue of $0.2M (-88.9% Y/Y) Press Release For further details see: Longeveron reports Q3 results